Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 3, 2010

Swiss TPH to Evaluate Telormedix’ Adjuvant for Malaria and Buruli Ulcer Immunization

  • Telormedix is teaming up with the Swiss Tropical and Public Health Institute (Swiss TPH) for a pilot study that aims to evaluate the firm’s TMX-201 adjuvant as part of developmental immunization strategies against malaria and Buruli ulcer. The pilot studies, to be carried out by researchers at the Swiss TPH, will compare Telormedix’ TMX-201 adjuvant with conventional adjuvant in combination with either a Plasmodium falciparum antigen candidate or a Mycobacterium ulcerans antigen candidate.

    Telormedix is focused on developing drugs that harness the innate immune system for the treatment of cancer and autoimmune diseases. The firm’s adjuvant pipeline includes TMX-201 and other second- generation TLR7 molecules.

    Lead therapeutic candidate, TMX-101, started in Phase I/II clinical development in June for the treatment of localized bladder cancer. The drug comprises a known immunomodulatory molecule that Telormedix says has a favorable safety profile and a demonstrated clinical efficacy in oncological and viral diseases. The firm has taken advantage of existing regulatory data and clinical experience to speed TMX-101 through preclinical development and into human trials.

    Telormedix’ second therapeutic candidate TMX-202 is a second-generation small molecule TLR7 molecule in preclinical development for the topical treatment of skin cancers, bladder cancers, and other indications. Discovered through a collaboration with the University of California San Diego, TMX-202 has already successfully completed a number of in vivo studies, the firm explains. Its third therapeutic program, designated TMX-30X, is focused on developing candidates for treating autoimmune diseases.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »